Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 57.5%

Neg 0% Neu 0% Pos 57.5%

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $67 to $120.